Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis

The recent introduction of ABP 501, an adalimumab biosimilar, in the treatment of rheumatic diseases was supported by a comprehensive comparability exercise with its originator. On the other hand, observational studies comparing adalimumab and ABP 501 in inflammatory arthritis are still lacking. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Becciolini, Andrea, Parisi, Simone, Caccavale, Rosalba, Bravi, Elena, Lumetti, Federica, Andracco, Romina, Volpe, Alessandro, Gardelli, Lucia, Girelli, Francesco, Di Donato, Eleonora, Santilli, Daniele, Lucchini, Gianluca, Ditto, Maria Chiara, Platè, Ilaria, Arrigoni, Eugenio, Mozzani, Flavio, Riva, Michele, Marchetta, Antonio, Fusaro, Enrico, Sandri, Gilda, Salvarani, Carlo, Paroli, Marino, Ariani, Alarico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949392/
https://www.ncbi.nlm.nih.gov/pubmed/35330335
http://dx.doi.org/10.3390/jpm12030335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949392/
https://www.ncbi.nlm.nih.gov/pubmed/35330335
http://dx.doi.org/10.3390/jpm12030335

Ejemplares similares